Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:31:28.291Z.
Calculation as of: 2026-10-06T16:31:28.291Z.
Quote observation: 2026-10-06T16:30:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 396f74b358d2be52688229160785b883c1ccba5e7e57b4b59ce0869c705c56f9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$410.85M
EV/EBITDA Ratio
N/A
TTM Avg
30.26x
3Y Avg
22.88x
5Y Avg
18.64x
Market Cap
$412.94M
EV/EBITDA Ratio
N/A
TTM Avg
5.73x
3Y Avg
28.73x
5Y Avg
28.73x
Market Cap
$414.16M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$396.99M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$417.78M
EV/EBITDA Ratio
N/A
TTM Avg
16.39x
3Y Avg
16.39x
5Y Avg
16.39x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $404.78M | N/A | N/A | N/A | N/A |
| Myriad Genetics, Inc. (MYGN)vs › | $410.85M | N/A | 30.26x | 22.88x | 18.64x |
| Neurogene Inc. (NGNE)vs › | $410.80M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $411.03M | N/A | N/A | N/A | N/A |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $412.94M | N/A | 5.73x | 28.73x | 28.73x |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $414.16M | N/A | N/A | N/A | N/A |
| MapLight Therapeutics, Inc. (MPLT)vs › | $396.99M | N/A | N/A | N/A | N/A |
| Prothena Corporation plc (PRTA)vs › | $417.78M | N/A | 16.39x | 16.39x | 16.39x |
| Rezolute, Inc. (RZLT)vs › | $418.87M | N/A | N/A | N/A | N/A |
| REGENXBIO Inc. (RGNX)vs › | $391.28M | N/A | 7.49x | 7.49x | 18.24x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
